Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HMGCR | P04035 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863507 | 1.00 | HSP90AB1 (0.67) | HSP90AB1POLBGAAMAPTNPC1 | |
| SCHEMBL24763383 | 0.86 | HSP90AB1 (0.50) | HSP90AB1POLBGAAMAPTNPC1 | |
| SCHEMBL1445838 | 0.85 | HPGD (0.59) | HSP90AB1POLBGAAMAPTNPC1 | |
| SCHEMBL2375910 | 0.85 | HPGD (0.62) | HSP90AB1POLBGAAMAPTALDH1A1 | |
| SCHEMBL25666683 | 0.84 | MAPT (0.54) | HSP90AB1GAAMAPTNPC1RAB9A | |
| SCHEMBL24939658 | 0.82 | MAPT (0.53) | HSP90AB1GAAMAPTNPC1RAB9A | |
| SCHEMBL6174178 | 0.82 | HSP90AB1 (0.48) | HSP90AB1POLBGAAMAPTRAB9A | |
| SCHEMBL7800202 | 0.82 | HTT (0.64) | HSP90AB1POLBGAAMAPTNPC1 | |
| SCHEMBL21591498 | 0.81 | MAPT (0.49) | HSP90AB1POLBGAAMAPTNPC1 | |
| SCHEMBL31085015 | 0.81 | MAPT (0.49) | HSP90AB1POLBGAAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-113302185-B | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-113302185-A | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020220562-A1 | BENZOFURAN-6-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2020-11-05 | — | — | WO | disclosed |
| CN-111116577-A | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2019-08-27 | — | — | US | disclosed |
| CN-106316813-A | 3-substituted 3-vinyl-2-hydroxy-1-aryl acetone and synthetic method thereof | 上海交通大学 | 2017-01-11 | — | — | CN | disclosed |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2015-10-08 | — | — | US | disclosed |
| CN-102712648-A | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| CN-102245587-A | Trpv1 antagonists | ABBOTT LAB | 2011-11-16 | — | — | CN | disclosed |
| CN-102203093-A | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2011-09-28 | — | — | CN | disclosed |
| CN-102186836-A | Trpv1 antagonists | ABBOTT LAB | 2011-09-14 | — | — | CN | disclosed |
| CN-102143959-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-08-03 | — | — | CN | disclosed |
| CN-101171230-A | Heterocyclic-substituted alkanamides useful as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-0983249-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED INDAZOLE DERIVATIVES | PFIZER PROD INC (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0983249-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED INDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-6011159-A | Processes and intermediates for preparing substituted indazole derivatives | PFIZER INC (US) | 2000-01-04 | — | — | US | disclosed |
| WO-1998050367-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED INDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | HSP90AB1 957/4885POLB 1468/4885GAA 306/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | HSP90AB1 3705/4885POLB 4827/4885GAA 3044/4885 |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | HSP90AB1 957/4885POLB 1468/4885GAA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.